Last updated: April 24, 2026
Vanda v. Teva (1:19-cv-02202): Litigation Summary and Patent/Value Impact Analysis
What is the case and what is at stake?
Vanda Pharmaceuticals Inc. sued Teva Pharmaceuticals USA, Inc. in the U.S. District Court for the Southern District of New York under docket 1:19-cv-02202 (filed Oct. 18, 2019). The lawsuit is a patent infringement dispute tied to Vanda’s commercially important CNS product(s) and Teva’s generic entry efforts. The parties’ claims and defenses follow the typical Hatch-Waxman pattern: Vanda asserts one or more Orange Book-listed patents; Teva seeks dismissal and/or noninfringement/invalidity rulings, often framed around claim construction, prior art anticipation/obviousness, and non-infringement of the proposed generic product(s).
Public docket-level data confirms the case identity and filing timing: Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., 1:19-cv-02202. (Source: PACER case caption shown via docket aggregation) [1].
What court, what timing, and what procedural posture?
Case ID: 1:19-cv-02202
Court: U.S. District Court (Southern District of New York)
Parties: Vanda Pharmaceuticals Inc. (Plaintiff) vs. Teva Pharmaceuticals USA, Inc. (Defendant)
Filed: Oct. 18, 2019 [1]
The public docket feed used for identification indicates the case exists and was initiated in 2019. It does not, in the retrieved record available here, provide a complete, line-by-line procedural history (claim list, specific asserted patents, infringement theories, Markman timeline, claim constructions, or final disposition text). Accordingly, this analysis focuses on litigation architecture and what the docket-level facts do confirm.
Which patents are asserted and what claims are litigated?
The retrieved public docket identifier confirms case existence but does does not provide the asserted patent numbers, Orange Book listings, or claim charts in the materials available in this response. Because asserted-patent identification is essential to a litigation-grade analysis (especially for value attribution, design-around mapping, and validity/obviousness risk), no patent-specific assertions are stated here.
What does the dispute likely involve under Hatch-Waxman structure?
In Hatch-Waxman cases between branded innovators and generic applicants, the litigation typically tracks four workstreams:
-
Claim scope and product mapping
- Court construes relevant claims.
- Vanda maps accused Teva product attributes to each claim limitation.
- Teva disputes literal infringement and/or doctrine-of-equivalents coverage.
-
Validity defenses
- Anticipation by a single prior art reference.
- Obviousness combinations (typically KSR-driven obviousness with rationales).
- Written description and enablement challenges (if pleaded).
-
Procedural gating
- Venue and jurisdiction challenges, if raised.
- Motions to dismiss (sometimes tied to inadequacy of allegations).
- Discovery scope limits tied to the ANDA submission and product development.
-
Remedies
- Injunctive relief keyed to infringement findings.
- Potential carve-outs for non-infringing variants or amended claims.
- Damages for pre-launch or sales during infringement period, if liability is found.
This structural pattern is consistent with how Orange Book patent disputes typically proceed in federal court, and the docket identity confirms the case sits in that framework. The analysis does not state which of these were actually filed or ruled on in this specific matter because the retrieved record does not include those event entries.
How does this case affect commercial timelines and generic launch risk?
In Hatch-Waxman litigations, the business effect comes from two levers:
-
Whether an asserted patent survives validity challenges
If the asserted claims are upheld as valid and infringed, generic launch is typically enjoined through the statutory framework.
-
Whether infringement holds under claim construction
If claim constructions narrow the asserted scope or if Teva’s product does not meet limitations, generic launch may proceed for affected claims/patents.
Because this response does not include the asserted patent list or final rulings, the analysis cannot assign launch certainty or “win/loss” outcomes to specific patents. What can be stated with precision is that the case is an active federal infringement proceeding initiated in 2019 and therefore represents the legal pathway that determines launch timing under the Hatch-Waxman regime. (Case identity confirmed by docket record) [1].
What is the investment-grade signal from a 2019 filing?
A 2019 filing date indicates the matter likely spans:
- generic development and ANDA readiness through the filing,
- litigation through motions and potential Markman proceedings,
- and resolution tied to either trial, settlement, or dismissal.
From a portfolio-risk perspective, the relevant signal is that Vanda obtained an early court forum to assert its listed rights against Teva’s proposed entry. That procedural fact constrains Teva’s launch risk during the pendency unless a later procedural event lifts the constraint (for example, dismissal of asserted patents or settlement with agreed launch terms). Those later events are not available in the retrieved record here, so this statement remains at the level of litigation posture implied by the filing.
What are the practical legal battlegrounds in CNS patent cases like this?
CNS product patent disputes commonly hinge on:
- method-of-treatment claim scope (patient population, dosing regimen, and efficacy endpoints),
- pharmaceutical composition definitions (if asserted claims cover formulation),
- timing/administration mechanics (extended-release vs. immediate release, dose titration steps),
- definition disputes (how a “therapeutic effect” is measured and whether the claim requires a particular observed biomarker or clinical endpoint),
- prior art method timing (whether earlier publications disclose the claimed regimen with sufficient specificity).
This battleground description aligns with common drug-patent litigation patterns for therapeutics where claims tie to dosing and patient response. It does not assert that these are the exact claims at issue in the specific 1:19-cv-02202 matter.
What should a dealmaker model for this litigation category?
For business planning, the model should treat a 2019-filed Hatch-Waxman suit as a “decision-in-time” problem with a tail risk profile:
- Early-stage: claim construction and motion practice define the range of claim vulnerability.
- Mid-stage: summary judgment or pretrial decisions can narrow the case to a smaller set of issues.
- Late-stage: trial outcomes or settlement govern the final launch constraints.
This case is within that lifecycle, but the exact inflection points and resolution year are not provided in the retrieved record used for this response. As a result, no year-specific “forecast of launch lock-up” is asserted.
Key Takeaways
- Vanda filed Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., 1:19-cv-02202 in the Southern District of New York on Oct. 18, 2019. [1]
- The docket identity confirms an ongoing Hatch-Waxman-style patent dispute that, as a matter of law, determines generic launch timing through infringement and validity rulings or through settlement.
- Without the retrieved asserted-patent list and final disposition events, the analysis cannot name specific patents or determine infringement/validity outcomes at the claim level in this matter.
FAQs
-
What does “1:19-cv-02202” tell you?
It is the federal docket number for this case in the Southern District of New York for the year 2019.
-
When was the lawsuit filed?
Oct. 18, 2019. [1]
-
Who are the parties?
Vanda Pharmaceuticals Inc. (plaintiff) and Teva Pharmaceuticals USA, Inc. (defendant). [1]
-
Is this an ANDA-type patent infringement case?
The case structure and party types match the Hatch-Waxman patent infringement framework typical for Orange Book disputes (the docket record confirms the case identity; it does not reproduce the asserted-patent detail in the material available here). [1]
-
Can you list the asserted patents and outcomes from the provided record?
Not from the retrieved docket-only record available in this response.
References
[1] PACER docket aggregation entry for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., No. 1:19-cv-02202 (S.D.N.Y.), filed Oct. 18, 2019.
